CareRA 试验:甲氨蝶呤诱导联合或不联合其他 csDMARDs 及短期糖皮质激素治疗类风湿关节炎的 5 年达标治疗结局
CareRA 试验 5 年随访比较早期 RA 不同初始治疗方案的结局。322 例中 252 例进入观察研究,203 例完成。高危患者各强化治疗 5 年 DAS28-CRP 和 HAQ 相当;低危患者起始 COBRA-Slim 者 DAS28-CRP 和 HAQ 优于单用 MTX 者。
要点
- 高危早期 RA 患者中,COBRA-Slim 与更复杂方案 5 年疗效相当。
- 低危患者起始 COBRA-Slim 的疾病活动和功能结局优于初始 MTX 单药。
- 5 年间 22% 患者启用生物制剂,25% 超桥接期用糖皮质激素>3 个月。
核心结论
- 所有含糖皮质激素桥接的强化治疗均显示优异的 5 年结局。
- 高危早期 RA 起始 COBRA-Slim 与更复杂治疗疗效相当。
- 低危早期 RA 起始 COBRA-Slim 优于初始 MTX 单药治疗。
研究设计与样本
- CareRA 随机对照试验 2 年结束后,符合条件患者进入 3 年观察性 CareRA-plus 研究。
- 322 例符合条件患者中 252 例(78%)进入 CareRA-plus,203 例(81%)完成研究。
- 按预后分组比较初始 MTX 单药联合糖皮质激素桥接(COBRA-Slim)与其他方案的 5 年结局。
主要发现
- 高危患者各治疗组 5 年 DAS28-CRP(p=0.539)和 HAQ(p=0.374)无显著差异。
- 低危患者起始 COBRA-Slim 者 DAS28-CRP(p<0.001)和 HAQ(p=0.041)低于初始 MTX 单药者。
- 研究完成时 114/203(56%)患者原始 DMARD 治疗从未强化,各组比例相当。
- 低危患者中 COBRA-Slim 组 10 例发生 18 次不良事件,初始 MTX 单药组 17 例发生 36 次(p=0.048)。
- 5 年间 22% 患者启用生物制剂,25% 超桥接期用糖皮质激素>3 个月,17%>6 个月。
关键数值与推荐
- 高危患者 5 年 DAS28-CRP 组间 p=0.539,HAQ 组间 p=0.374。
- 低危患者 5 年 DAS28-CRP 组间 p<0.001,HAQ 组间 p=0.041。
- 低危患者不良事件 COBRA-Slim 组 18 次/10 例 vs 初始 MTX 单药组 36 次/17 例,p=0.048。
- 5 年 22% 患者启用生物制剂,25% 用糖皮质激素>3 个月,17%>6 个月。
临床怎么用
- 高危早期 RA 可考虑起始 COBRA-Slim,疗效与更复杂方案相当。
- 低危早期 RA 起始 COBRA-Slim 可能优于初始 MTX 单药,且不良事件较少。
- 多数患者 5 年内无需强化原始 DMARD 治疗,生物制剂和长期糖皮质激素使用比例有限。
局限性
- 3 年观察期部分患者失访,203/252(81%)完成研究。
- 原文未报告随机化后各治疗组的具体样本量分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare outcomes of different treatment schedules from the care in early rheumatoid arthritis (CareRA) trial over 5 years. METHODS: Patients with RA completing the 2-year CareRA randomised controlled trial were eligible for the 3-year observational CareRA-plus study. 5-year outcomes after randomisation to initial methotrexate (MTX) monotherapy with glucocorticoid bridging (COBRA-Slim) were compared with MTX step-up without glucocorticoids or conventional synthetic disease-modifying antirheumatic drug (DMARD) combinations with glucocorticoid bridging, per prognostic patient group. Disease activity (Disease Activity Score based on 28 joints calculated with C reactive protein (DAS28-CRP)) and functionality (Health Assessment Questionnaire (HAQ)) were compared between treatment arms using longitudinal models; safety and drug use were detailed. RESULTS: Of 322 eligible patients, 252 (78%) entered CareRA-plus, of which 203 (81%) completed the study. Treatments for high-risk patients resulted in comparable DAS28-CRP (p=0.539) and HAQ scores over 5 years (p=0.374). Low-risk patients starting COBRA-Slim had lower DAS28-CRP (p<0.001) and HAQ scores (p=0.041) than those starting only on MTX. At study completion, 114/203 (56%) patients never had their original DMARD therapy intensified, with comparable rates between all treatments. Safety was comparable between treatments in high-risk patients. In low-risk patients, there were 18 adverse events in 10 COBRA-Slim and 36 in 17 patients treated with initial MTX monotherapy (p=0.048). Over 5 years, 22% of patients initiated biologics, 25% took glucocorticoids for >3 months and 17% for >6 months outside the bridging period. CONCLUSIONS: All intensive treatments with glucocorticoids bridging demonstrated excellent 5 year outcomes. Initiating COBRA-Slim was comparably effective as more complex treatments for high-risk patients with early RA and more effective than initial MTX monotherapy for low-risk patients with limited need for biologics and chronic glucocorticoid use.
引用
- Stouten V, Westhovens R, Pazmino S, et al. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. Ann Rheum Dis. 2021. PMID: 33811036. doi:10.1136/annrheumdis-2020-219825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。